Erwinase® (erwinia asparaginase) is a product from EUSA Pharma. Asparaginases are a cornerstone of treatment for acute lymphoblastic leukaemia (ALL) and are used for remission and treatment in all paediatric and the majority of adult treatment protocols. As part of well-designed treatment programmes long-term, event-free, survival rates in children are currently around 80% and overall survival rates are close to 90%. Adults have a poorer tolerance to some chemotherapy regimes, but overall survival rates of up to 50% are reported.
Erwinase plays a vital role in treatment for many people suffering from ALL and thereby giving hope for a better quality of life for years to come.